Frederik MarmÃ©

List of Publications by Year
in descending order

125 papers	7,213 citations	117625 34 h-index	62596 80 g-index
128 all docs	128 docs citations	128 times ranked	10638 citing authors

#	Article	IF	Citations
1	Olaparib plus Bevacizumab as First-Line Maintenance in Ovarian Cancer. New England Journal of Medicine, 2019, 381, 2416-2428.	27.0	1,176
2	Large-scale genotyping identifies 41 new loci associated with breast cancer risk. Nature Genetics, 2013, 45, 353-361.	21.4	960
3	^{68}Ga-FAPI PET/CT: Tracer Uptake in 28 Different Kinds of Cancer. Journal of Nuclear Medicine, 2019, 60, 801-805.	5.0	874
4	Genome-wide association analysis of more than 120,000 individuals identifies 15 new susceptibility loci for breast cancer. Nature Genetics, 2015, 47, 373-380.	21.4	513
5	Development of Fibroblast Activation Protein–Targeted Radiotracers with Improved Tumor Retention. Journal of Nuclear Medicine, 2019, 60, 1421-1429.	5.0	281
6	Palbociclib for Residual High-Risk Invasive HR-Positive and HER2-Negative Early Breast Cancer–The Penelope-B Trial. Journal of Clinical Oncology, 2021, 39, 1518-1530.	1.6	153
7	Low penetrance breast cancer susceptibility loci are associated with specific breast tumor subtypes: findings from the Breast Cancer Association Consortium. Human Molecular Genetics, 2011, 20, 3289-3303.	2.9	152
8	Prognosis of breast cancer molecular subtypes in routine clinical care: A large prospective cohort study. BMC Cancer, 2016, 16, 734.	2.6	126
9	A Randomized, Phase III Trial to Evaluate Rucaparib Monotherapy as Maintenance Treatment in Patients With Newly Diagnosed Ovarian Cancer (ATHENA–MONO/GOG-3020/ENGOT-ov45). Journal of Clinical Oncology, 2022, 40, 3952-3964.	1.6	125
10	Genetically Predicted Body Mass Index and Breast Cancer Risk: Mendelian Randomization Analyses of Data from 145,000 Women of European Descent. PLoS Medicine, 2016, 13, e1002105.	8.4	118
11	Design and Development of ^{99m}Tc-Labeled FAPI Tracers for SPECT Imaging and [188]Re Therapy. Journal of Nuclear Medicine, 2020, 61, 1507-1513.	5.0	110
12	Evidence that breast cancer risk at the 2q35 locus is mediated through IGFBP5 regulation. Nature Communications, 2014, 5, 4999.	12.8	105
13	Prevalence of deleterious germline variants in risk genes including BRCA1/2 in consecutive ovarian cancer patients (AGO-TR-1). PLoS ONE, 2017, 12, e0186043.	2.5	105
14	Bevacizumab and platinum-based combinations for recurrent ovarian cancer: a randomised, open-label, phase 3 trial. Lancet Oncology, The, 2020, 21, 699-709.	10.7	104
15	Identification of four novel susceptibility loci for oestrogen receptor negative breast cancer. Nature Communications, 2016, 7, 11375.	12.8	93
16	The role of genetic breast cancer susceptibility variants as prognostic factors. Human Molecular Genetics, 2012, 21, 3926-3939.	2.9	80
17	Functional mechanisms underlying pleiotropic risk alleles at the 19p13.1 breast–ovarian cancer susceptibility locus. Nature Communications, 2016, 7, 12675.	12.8	78
18	Fine-Scale Mapping of the 5q11.2 Breast Cancer Locus Reveals at Least Three Independent Risk Variants Regulating MAP3K1. American Journal of Human Genetics, 2015, 96, 5-20.	6.2	76

#	Article	IF	Citations
19	*BRCA2* Hypomorphic Missense Variants Confer Moderate Risks of Breast Cancer. Cancer Research, 2017, 77, 2789-2799.	0.9	75
20	A Biomarker-enriched, Randomized Phase II Trial of Adavosertib (AZD1775) Plus Paclitaxel and Carboplatin for Women with Platinum-sensitive *TP53*-mutant Ovarian Cancer. Clinical Cancer Research, 2020, 26, 4767-4776.	7.0	68
21	Genetic modifiers of CHEK2*1100delC-associated breast cancer risk. Genetics in Medicine, 2017, 19, 599-603.	2.4	67
22	TROPiCS-02: A Phase III study investigating sacituzumab govitecan in the treatment of HR+/HER2-metastatic breast cancer. Future Oncology, 2020, 16, 705-715.	2.4	62
23	Double-Blind, Placebo-Controlled, Randomized Phase III Trial Evaluating Pertuzumab Combined With Chemotherapy for Low Tumor Human Epidermal Growth Factor Receptor 3 mRNAâ€"Expressing Platinum-Resistant Ovarian Cancer (PENELOPE). Journal of Clinical Oncology, 2016, 34, 2516-2525.	1.6	60
24	Chemotherapy de-escalation using an 18F-FDG-PET-based pathological response-adapted strategy in patients with HER2-positive early breast cancer (PHERGain): a multicentre, randomised, open-label, non-comparative, phase 2 trial. Lancet Oncology, The, 2021, 22, 858-871.	10.7	60
25	Evidence that the 5p12 Variant rs10941679 Confers Susceptibility to Estrogen-Receptor-Positive Breast Cancer through FGF10 and MRPS30 Regulation. American Journal of Human Genetics, 2016, 99, 903-911.	6.2	59
26	Fulvestrant-Palbociclib vs Letrozole-Palbociclib as Initial Therapy for Endocrine-Sensitive, Hormone Receptorâ€"Positive, *ERBB2*-Negative Advanced Breast Cancer. JAMA Oncology, 2021, 7, 1791.	7.1	56
27	Phase Ib study evaluating safety and clinical activity of the anti-HER3 antibody lumretuzumab combined with the anti-HER2 antibody pertuzumab and paclitaxel in HER3-positive, HER2-low metastatic breast cancer. Investigational New Drugs, 2018, 36, 848-859.	2.6	55
28	Fine-mapping of the HNF1B multicancer locus identifies candidate variants that mediate endometrial cancer risk. Human Molecular Genetics, 2015, 24, 1478-1492.	2.9	50
29	Prognostic Cancer Gene Expression Signatures: Current Status and Challenges. Cells, 2021, 10, 648.	4.1	47
30	Utility of the CPS+EG staging system in hormone receptor-positive, human epidermal growth factor receptor 2-negative breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2016, 53, 65-74.	2.8	46
31	The impact of human adipose tissue-derived stem cells on breast cancer cells: implications for cell-assisted lipotransfers in breast reconstruction. Stem Cell Research and Therapy, 2017, 8, 121.	5.5	43
32	COOLHAIR: a prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing (neo)adjuvant chemotherapy for early breast cancer. Breast Cancer Research and Treatment, 2019, 173, 135-143.	2.5	41
33	Therapy response and prognosis of patients with early breast cancer with low positivity for hormone receptors â€" An analysis of 2765 patients from neoadjuvant clinical trials. European Journal of Cancer, 2021, 148, 159-170.	2.8	41
34	Fine-mapping identifies two additional breast cancer susceptibility loci at 9q31.2. Human Molecular Genetics, 2015, 24, 2966-2984.	2.9	40
35	Identification and characterization of novel associations in the CASP8/ALS2CR12 region on chromosome 2 with breast cancer risk. Human Molecular Genetics, 2015, 24, 285-298.	2.9	38
36	Polymorphisms in a Putative Enhancer at the 10q21.2 Breast Cancer Risk Locus Regulate NRBF2 Expression. American Journal of Human Genetics, 2015, 97, 22-34.	6.2	37

#	ARTICLE	IF	CITATIONS
37	Breast Cancers with a *BRCA1*-like DNA Copy Number Profile Recur Less Often Than Expected after High-Dose Alkylating Chemotherapy. Clinical Cancer Research, 2015, 21, 763-770.	7.0	34
38	Deleterious somatic variants in 473 consecutive individuals with ovarian cancer: results of the observational AGO-TR1 study (NCT02222883). Journal of Medical Genetics, 2019, 56, 574-580.	3.2	34
39	DNA methylation array analysis identifies breast cancer associated *RPTOR*, *MGRN1* and *RAPSN* hypomethylation in peripheral blood DNA. Oncotarget, 2016, 7, 64191-64202.	1.8	33
40	An intergenic risk locus containing an enhancer deletion in 2q35 modulates breast cancer risk by deregulating IGFBP5 expression. Human Molecular Genetics, 2016, 25, 3863-3876.	2.9	33
41	Efficacy of nab-paclitaxel does not seem to be associated with SPARC expression in metastatic breast cancer. Anticancer Research, 2014, 34, 6609-15.	1.1	32
42	Association of breast cancer risk with genetic variants showing differential allelic expression: Identification of a novel breast cancer susceptibility locus at 4q21. Oncotarget, 2016, 7, 80140-80163.	1.8	31
43	Plasma hyaluronic acid level as a prognostic and monitoring marker of metastatic breast cancer. International Journal of Cancer, 2016, 138, 2499-2509.	5.1	31
44	Identification of independent association signals and putative functional variants for breast cancer risk through fine-scale mapping of the 12p11 locus. Breast Cancer Research, 2016, 18, 64.	5.0	31
45	Efficacy and safety of everolimus plus exemestane in postmenopausal women with hormone receptorâ€positive, human epidermal growth factor receptor 2â€negative locally advanced or metastatic breast cancer: Results of the singleâ€arm, phase IIIB 4EVER trial. International Journal of Cancer, 2019, 144, 877-885.	5.1	31
46	Fibroblast growth factor receptor 4 gene (*FGFR4*) 388Arg allele predicts prolonged survival and platinum sensitivity in advanced ovarian cancer. International Journal of Cancer, 2012, 131, E586-91.	5.1	29
47	Subgroup analysis of patients with HER2-negative metastatic breast cancer in the second-line setting from a phase 3, open-label, randomized study of eribulin mesilate versus capecitabine. Breast Cancer, 2018, 25, 370-374.	2.9	28
48	The G protein-coupled estrogen receptor (GPER/GPR30) may serve as a prognostic marker in early-stage cervical cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 13-19.	2.5	27
49	Immune-related Gene Expression Predicts Response to Neoadjuvant Chemotherapy but not Additional Benefit from PD-L1 Inhibition in Women with Early Triple-negative Breast Cancer. Clinical Cancer Research, 2021, 27, 2584-2591.	7.0	27
50	An international, biomarker-directed, randomized, phase II trial of AZD1775 plus paclitaxel and carboplatin (P/C) for the treatment of women with platinum-sensitive, TP53-mutant ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5506-5506.	1.6	26
51	Mcl-1 confers protection of Her2-positive breast cancer cells to hypoxia: therapeutic implications. Breast Cancer Research, 2016, 18, 26.	5.0	25
52	Fine-Scale Mapping of the 4q24 Locus Identifies Two Independent Loci Associated with Breast Cancer Risk. Cancer Epidemiology Biomarkers and Prevention, 2015, 24, 1680-1691.	2.5	24
53	Identification and Characterization of Cancer Cells That Initiate Metastases to the Brain and Other Organs. Molecular Cancer Research, 2021, 19, 688-701.	3.4	22
54	CD24 Ala57Val polymorphism predicts pathologic complete response to sequential anthracycline- and taxane-based neoadjuvant chemotherapy for primary breast cancer. Breast Cancer Research and Treatment, 2012, 132, 819-831.	2.5	21

#	ARTICLE	IF	CITATIONS
55	Association of genetic susceptibility variants for type 2 diabetes with breast cancer risk in women of European ancestry. Cancer Causes and Control, 2016, 27, 679-693.	1.8	21
56	Human leucocyte antigen class I in hormone receptor-positive, HER2-negative breast cancer: association with response and survival after neoadjuvant chemotherapy. Breast Cancer Research, 2019, 21, 142.	5.0	21
57	SNP-SNP interaction analysis of NF-κB signaling pathway on breast cancer survival. Oncotarget, 2015, 6, 37979-37994.	1.8	20
58	Diagnosis of Li-Fraumeni Syndrome: Differentiating *TP53* germline mutations from clonal hematopoiesis. Human Mutation, 2018, 39, 2040-2046.	2.5	20
59	CD24 polymorphisms in breast cancer: impact on prognosis and risk. Breast Cancer Research and Treatment, 2013, 137, 927-937.	2.5	19
60	The cellular ratio of immune tolerance (immunoCRIT) is a definite marker for aggressiveness of solid tumors and may explain tumor dissemination patterns. Epigenetics, 2013, 8, 1226-1235.	2.7	19
61	Plasma S100P level as a novel prognostic marker of metastatic breast cancer. Breast Cancer Research and Treatment, 2016, 157, 329-338.	2.5	18
62	No clinical utility of KRAS variant rs61764370 for ovarian or breast cancer. Gynecologic Oncology, 2016, 141, 386-401.	1.4	18
63	Clonal Hematopoiesis–Associated Gene Mutations in a Clinical Cohort of 448 Patients With Ovarian Cancer. Journal of the National Cancer Institute, 2022, 114, 565-570.	6.3	17
64	*BRCA1*–like profile predicts benefit of tandem high dose epirubicin–cyclophospamide–thiotepa in high risk breast cancer patients randomized in the WSG–AM01 trial. International Journal of Cancer, 2016, 139, 882-889.	5.1	16
65	Second breast conserving therapy after ipsilateral breast tumor recurrence – a 10-year experience of re-irradiation. Journal of Contemporary Brachytherapy, 2019, 11, 312-319.	0.9	15
66	Prophylaxis and Management of Skin Toxicities. Breast Care, 2019, 14, 72-77.	1.4	15
67	Genetic variation at CYP3A is associated with age at menarche and breast cancer risk: a case-control study. Breast Cancer Research, 2014, 16, R51.	5.0	14
68	Inherited variants in the inner centromere protein (INCENP) gene of the chromosomal passenger complex contribute to the susceptibility of ER-negative breast cancer. Carcinogenesis, 2015, 36, 256-271.	2.8	14
69	Immunotherapy in Breast Cancer. Oncology Research and Treatment, 2016, 39, 335-345.	1.2	14
70	Prediction of pathological complete response in breast cancer patients during neoadjuvant chemotherapy: Is shear wave elastography a useful tool in clinical routine?. European Journal of Radiology, 2020, 128, 109025.	2.6	14
71	Bevacizumab-based treatment as salvage therapy in patients with recurrent symptomatic brain metastases. Neuro-Oncology Advances, 2020, 2, vdaa038.	0.7	14
72	Mismatch Repair Deficiency Drives Durable Complete Remission by Targeting Programmed Death Receptor 1 in a Metastatic Luminal Breast Cancer Patient. Breast Care, 2019, 14, 53-59.	1.4	13

#	Article	IF	Citations
73	Neoadjuvant epirubicin, gemcitabine and docetaxel for primary breast cancer: Long‐term survival data and major prognostic factors based on two consecutive neoadjuvant phase I/II trials. International Journal of Cancer, 2013, 133, 1006-1015.	5.1	12
74	Predictors of Residual Tumor in Breast-Conserving Therapy. Annals of Surgical Oncology, 2015, 22, 451-458.	1.5	12
75	Fine-Mapping of the 1p11.2 Breast Cancer Susceptibility Locus. PLoS ONE, 2016, 11, e0160316.	2.5	12
76	First-in-human phase I/II dose-escalation study of IMAB027 in patients with recurrent advanced ovarian cancer (OVAR): Preliminary data of phase I part.. Journal of Clinical Oncology, 2015, 33, 5537-5537.	1.6	12
77	Risk Assessment after Neoadjuvant Chemotherapy in Luminal Breast Cancer Using a Clinicomolecular Predictor. Clinical Cancer Research, 2018, 24, 3358-3365.	7.0	11
78	Antibody-Drug Conjugates for Breast Cancer. Oncology Research and Treatment, 2022, 45, 26-36.	1.2	11
79	Treatment of Luminal Metastatic Breast Cancer beyond CDK4/6 Inhibition: Is There a Standard of Care in Clinical Practice?. Breast Care, 2021, 16, 115-128.	1.4	10
80	Phase III postneoadjuvant study evaluating sacituzumab govitecan, an antibody drug conjugate in primary HER2-negative breast cancer patients with high relapse risk after standard neoadjuvant treatment: SASCIA.. Journal of Clinical Oncology, 2021, 39, TPS602-TPS602.	1.6	10
81	A Small Hypoxia Signature Predicted pCR Response to Bevacizumab in the Neoadjuvant GeparQuinto Breast Cancer Trial. Clinical Cancer Research, 2020, 26, 1896-1904.	7.0	9
82	Ovarian Cancer–Specific BRCA-like Copy-Number Aberration Classifiers Detect Mutations Associated with Homologous Recombination Deficiency in the AGO-TR1 Trial. Clinical Cancer Research, 2021, 27, 6559-6569.	7.0	9
83	Genetic variation in the immunosuppression pathway genes and breast cancer susceptibility: a pooled analysis of 42,510 cases and 40,577 controls from the Breast Cancer Association Consortium. Human Genetics, 2016, 135, 137-154.	3.8	8
84	ï»¿Preclinical evaluation of peptide-based radiotracers for integrin $\alpha v\beta 6$-positive pancreatic carcinoma. Nuklearmedizin - NuclearMedicine, 2019, 58, 309-318.	0.7	8
85	Utility of the CPS+EG scoring system in triple-negative breast cancer treated with neoadjuvant chemotherapy. European Journal of Cancer, 2021, 153, 203-212.	2.8	8
86	Clinical Relevance of Collagen Protein Degradation Markers C3M and C4M in the Serum of Breast Cancer Patients Treated with Neoadjuvant Therapy in the GeparQuinto Trial. Cancers, 2019, 11, 1186.	3.7	7
87	T-DM1 as a New Treatment Option for Patients with Metastatic HER2-positive Breast Cancer in Clinical Practice. Anticancer Research, 2015, 35, 5085-90.	1.1	7
88	A low‐frequency haplotype spanning SLX4/FANCP constitutes a new risk locus for early‐onset breast cancer (<60 years) and is associated with reduced DNA repair capacity. International Journal of Cancer, 2018, 142, 757-768.	5.1	6
89	Potential Interplay of the Gatipotuzumab Epitope TA-MUC1 and Estrogen Receptors in Ovarian Cancer. International Journal of Molecular Sciences, 2019, 20, 295.	4.1	6
90	Locoregional risk assessment after neoadjuvant chemotherapy in patients with primary breast cancer: clinical utility of the CPS+EG score. Breast Cancer Research and Treatment, 2019, 177, 437-446.	2.5	5

#	ARTICLE	IF	CITATIONS
91	Prediction of local recurrence risk after neoadjuvant chemotherapy in patients with primary breast cancer: Clinical utility of the MD Anderson Prognostic Index. PLoS ONE, 2019, 14, e0211337.	2.5	5
92	Extracapsular Lymph Node Involvement in Ovarian Carcinoma. Cancers, 2019, 11, 924.	3.7	4
93	Phase III randomised trial comparing intense dose-dense chemotherapy to tailored dose-dense chemotherapy in high-risk early breast cancer (GAIN-2). European Journal of Cancer, 2021, 156, 138-148.	2.8	4
94	Results of a phase II clinical trial to evaluate a re-challenge of intraperitoneal catumaxomab for treatment of malignant ascites (MA) due to epithelial cancer (SECIMAS).. Journal of Clinical Oncology, 2013, 31, 5582-5582.	1.6	4
95	A randomized phase II study to determine the efficacy and tolerability of two doses of eribulin plus lapatinib in trastuzumab-pretreated patients with HER-2-positive metastatic breast cancer (E-VITA). Anti-Cancer Drugs, 2019, 30, 394-401.	1.4	3
96	The impact of mammalian target of rapamycin inhibition on bone health in postmenopausal women with hormone receptor-positive advanced breast cancer receiving everolimus plus exemestane in the phase IIIb 4EVER trial. Journal of Bone Oncology, 2019, 14, 100199.	2.4	3
97	PENELOPE/AGO-OVAR 2.20: A double-blind placebo (PLA)-controlled randomized phase III ENGOT trial evaluating chemotherapy (CT) with or without pertuzumab (P) for platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2014, 32, TPS5613-TPS5613.	1.6	3
98	Efficacy and safety of chemotherapy (CT) Â± pertuzumab (P) for platinum-resistant ovarian cancer (PROC): AGO-OVAR 2.20/ENGOT-ov14/PENELOPE double-blind placebo-controlled randomized phase III trial.. Journal of Clinical Oncology, 2015, 33, 5504-5504.	1.6	3
99	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2019, 37, TPS5601-TPS5601.	1.6	3
100	NOGGO Ov-42/MAMOC: Rucaparib maintenance after bevacizumab maintenance following carboplatin-based first line-chemotherapy in ovarian cancer patients.. Journal of Clinical Oncology, 2020, 38, TPS6102-TPS6102.	1.6	3
101	TA-MUC1 as detected by the fully humanized, therapeutic antibody Gatipotzumab predicts poor prognosis in cervical cancer. Journal of Cancer Research and Clinical Oncology, 2018, 144, 1899-1907.	2.5	2
102	Fibroblast growth factor receptor 4 (FGFR4) as detected by immunohistochemistry is associated with postoperative residual disease in ovarian cancer. Journal of Cancer Research and Clinical Oncology, 2019, 145, 2251-2259.	2.5	2
103	Palbociclib combined with endocrine treatment in breast cancer patients with high relapse risk after neoadjuvant chemotherapy: Subgroup analyses of premenopausal patients in PENELOPE-B.. Journal of Clinical Oncology, 2021, 39, 518-518.	1.6	2
104	Incidence of germline mutations in risk genes including <i>BRCA1/2</i> in consecutive ovarian cancer (OC) patients (AGO TR-1).. Journal of Clinical Oncology, 2016, 34, 5538-5538.	1.6	2
105	DNA methylation profiling identifies two distinct subgroups in breast cancers with low hormone receptor expression, mainly associated with HER2 amplification status. Clinical Epigenetics, 2021, 13, 184.	4.1	2
106	Luminal Metastatic Breast Cancer. Breast Care, 2019, 14, 99-101.	1.4	1
107	What is the evidence for lymphadenectomy in presumed early ovarian cancer?. Archives of Gynecology and Obstetrics, 2019, 299, 1-5.	1.7	1
108	The PACOVAR-trial: A multicenter phase I trial of pazopanib (GW786034) and metronomic cyclophosphamide in patients with recurrent platinum-resistant ovarian cancer.. Journal of Clinical Oncology, 2015, 33, 5557-5557.	1.6	1

#	ARTICLE	IF	CITATIONS
109	COOLHAIR: A prospective randomized trial to investigate the efficacy and tolerability of scalp cooling in patients undergoing neoadjuvant chemotherapy for early breast cancer.. Journal of Clinical Oncology, 2017, 35, 525-525.	1.6	1
110	BRCA1 like copy number profiles to predict benefit of intensified alkylating chemotherapy in breast cancer.. Journal of Clinical Oncology, 2013, 31, 11023-11023.	1.6	1
111	BRCA1-like copy number profiles to predict benefit of high-dose alkylating chemotherapy in high-risk breast cancer (BC): Results from randomized WSG AM-01 trial.. Journal of Clinical Oncology, 2014, 32, 11018-11018.	1.6	1
112	Correlation of the tumor mutational burden with the composition of the immune cell subpopulations in peripheral blood of triple-negative breast cancer patients undergoing neoadjuvant therapy with durvalumab: Results from the prospectively randomized GeparNuevo trial.. Journal of Clinical Oncology, 2019, 37, 588-588.	1.6	1
113	A randomized phase II trial of mirvetuximab soravtansine (IMGN853), in folate receptor alpha (FRα)-high recurrent ovarian cancer eligible for platinum-based chemotherapy.. Journal of Clinical Oncology, 2022, 40, TPS5618-TPS5618.	1.6	1
114	OReO/ENGOT Ov-38 trial: Impact of maintenance olaparib rechallenge according to ovarian cancer patient prognosisâ€"An exploratory joint analysis of the BRCA and non-BRCA cohorts.. Journal of Clinical Oncology, 2022, 40, 5558-5558.	1.6	1
115	Neoadjuvant epirubicin, gemcitabine, and docetaxel for primary breast cancer: Survival and prognostic factors in two consecutive neoadjuvant phase I/II trials.. Journal of Clinical Oncology, 2012, 30, 1096-1096.	1.6	0
116	Circulating tumor cells in metastatic breast cancer: Are they a strong and independent predictor of poor progression-free and overall survival?. Journal of Clinical Oncology, 2012, 30, 1090-1090.	1.6	0
117	Prognostic impact of changes in circulating tumor cells (CTC) in metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2013, 31, 11012-11012.	1.6	0
118	Expression of SPARC and response to nab-paclitaxel (nab-p) in patients (pts) with metastatic breast cancer (MBC).. Journal of Clinical Oncology, 2014, 32, e12009-e12009.	1.6	0
119	Interim analysis of a phase I/II open label, dose-escalating study to investigate safety, tolerability, and preliminary efficacy of the trifunctional anti-HER2/neu x anti-CD3 antibody ertumaxomab in patients with HER2/neu expressing solid tumors progressing after standard therapy.. Journal of Clinical Oncology, 2014, 32, 3055-3055.	1.6	0
120	DNA methylation array analyses to identify HYAL2 methylation in peripheral blood as a marker for the detection of early breast cancer.. Journal of Clinical Oncology, 2014, 32, 26-26.	1.6	0
121	Predictive value of ultra-high ESR1 mRNA expression in early breast cancer.. Journal of Clinical Oncology, 2016, 34, e12045-e12045.	1.6	0
122	Comparison of an automated cartridge-based system for mRNA assessment with central immunohistochemistry in the neoadjuvant GeparX trial.. Journal of Clinical Oncology, 2019, 37, 3075-3075.	1.6	0
123	Abstract P5-13-36: Germline <i>BRCA</i>1/2 and other predisposition genes in high-risk early-stage HR+/HER2- breast cancer (BC) patients treated with endocrine therapy (ET) with or without palbociclib: A secondary analysis from the PENELOPE-B study. Cancer Research, 2022, 82, P5-13-36-P5-13-36.	0.9	0
124	Abstract PD2-04: Molecular plasticity of luminal breast cancer and response to CDK 4/6 inhibition - The biomarker program of the PENELOPE-B trial investigating post-neoadjuvant palbociclib. Cancer Research, 2022, 82, PD2-04-PD2-04.	0.9	0
125	AGO-OVAR 2.29 (ENGOT-ov34): Atezolizumab in combination with bevacizumab and chemotherapy versus bevacizumab and chemotherapy in recurrent ovarian cancer (ROC).. Journal of Clinical Oncology, 2022, 40, TPS5611-TPS5611.	1.6	0